Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Intellia Therapeutics (NTLA) through the VizualStocks API.
Collaboration revenue primarily representing reimbursements due from Regeneron under the co-development and co-promotion agreement for Intellia's transthyretin amyloidosis program, nexiguran ziclumeran (nex-z, formerly NTLA-2001). This is a period revenue flow, separate from research-license revenue and hemophilia cost sharing.
attrCollaborationRevenueLicense and research revenue recognized under Intellia's agreement granting AvenCell access to genome editing for universal CAR-T cell therapies, after intra-entity profit eliminations. This excludes separately disclosed material shipments and co-development cost sharing, and includes the 2024 recognition of previously eliminated profit.
avenCellLicenseRevenueRevenue from research materials shipped to AvenCell under Intellia's license and collaboration agreement for genome edited universal CAR-T cell therapies. This is reported separately from license revenue and co-development cost sharing.
avenCellMaterialsRevenueRevenue recognized from Regeneron reimbursements for work on the hemophilia B program under Intellia's 2016 collaboration agreement. This follows the September 2024 end of the hemophilia B co-development agreement and excludes development milestone consideration.
hemophiliaBCostReimbursementRevenueReductions to Intellia's collaboration revenue for costs shared under the Regeneron hemophilia A and B co-development agreements, stored as negative USD. The hemophilia B co-development agreement ended in September 2024; subsequent hemophilia B service reimbursements are a separate revenue series.
hemophiliaCollaborationContraRevenueRevenue recognized for Intellia's technology license and collaboration with Kyverna to develop gene edited CAR-T cell therapies. The original license transaction price was fully recognized by March 2023; this series excludes research material shipments.
kyvernaLicenseRevenueRevenue recognized for licenses and research under Intellia's 2016 Regeneron agreement, its 2020 amendment and the technology collaboration extension. This excludes separately disclosed ATTR cost sharing, hemophilia reimbursements and milestone consideration.
regeneronLicenseResearchRevenueNet revenue or contra-revenue from shared development costs under Intellia's AvenCell co-development and co-funding agreement, with revenue reductions stored as negative USD. The agreement ended in the second quarter of 2023; license revenue and material shipments are separate series.
avenCellCoDevelopmentNetRevenueRevenue from shared research costs under the September 2023 Regeneron amendment to develop gene editing therapies for neurological and muscular diseases. The research collaboration for those targets expired in September 2025.
regeneronNeurologicalMuscularRevenueRevenue under Intellia's CRISPR technology license and research collaboration with SparingVision for ocular diseases, recognized as research obligations are satisfied. The agreement ended in October 2025, when the remaining transaction price was recognized after reflecting returned shares.
sparingVisionCollaborationRevenue